IGM Biosciences, Inc. Gains 96.73%

IGM Biosciences, Inc. (IGMS:NASDAQ) shot up at $29.49, representing a gain of 96.7%. The stock got featured on our News Catalysts scanner on Tue, Mar 29, 2022 at 03:14 PM in the 'AGREEMENT' category. From Mon, Mar 14, 2022, the stock recorded 50.00% Up Days and 54.55% Green Days
About IGM Biosciences, Inc. (IGMS:NASDAQ)
IGM Biosciences Inc is a biotechnology company involved in the development of engineered IgM antibodies for the treatment of cancer patients. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Top 10 Gainers:
- IGM Biosciences, Inc. (IGMS:NASDAQ), 96.73%
- PhaseBio Pharmaceuticals, Inc. (PHAS:NASDAQ), 46.09%
- China SXT Pharmaceuticals, Inc. (SXTC:NASDAQ), 45.4%
- Oblong Inc. (OBLG:NASDAQ), 45%
- Clever Leaves Holdings Inc. (CLVR:NASDAQ), 40.31%
- MicroVision, Inc. (MVIS:NASDAQ), 32.78%
- ECMOHO Limited (MOHO:NASDAQ), 27.95%
- LianBio (LIAN:NASDAQ), 27.5%
- BBQ Holdings, Inc. (DAVE:NASDAQ), 27.45%
- Kinnate Biopharma Inc. (KNTE:NASDAQ), 25.94%